EE329 Budget Impact Analysis of Adding Risankizumab and Upadacitinib for the Treatment of Inflammatory Bowel Disease in the Kingdom of Saudi Arabia
Abstract
Authors
M. Mosli A. Almutairdi A.K. Abdulrahman A.N. Fasseeh A. Abd-El Aziz A. Jaheen A. Anwar B. Elezbawy B. Alharbi E. Al Tawil H. Al-Abdulkarim H. Alqasim I. Eldeeb K. Ahmed El-Fass L. Alanizy M. Tannira R. Almehizia S. Abaza W. Iskandarani Z. Kaló